Insights Series S3 E6: Dr Raymond Benza on HDAC inhibition in PAH

Dr. Raymond Benza, System Director of Pulmonary Hypertension at Mount Sinai Icahn School of Medicine, New York City, Principal Investigator of the Phase II study of CS1, and member of Cereno’s Scientific Advisory Board, talks about the future of treating pulmonary arterial hypertension (PAH) including why histone deacetylase inhibition (HDACi) is an important target for novel therapies, why CS1 represents a different approach to the management of PAH in terms of multiple modes of action and how CS1 could impact the management of PAH in the future in terms of clinical and functional outcomes.

Watch here.